PCD Clinical Trial
Official title:
A Clinical Investigation Determining the Discriminative Ability of the NIOX VERO NASAL to Differentiate Subjects With Primary Ciliary Dyskinesia From Healthy Controls
| Verified date | May 2017 |
| Source | Aerocrine AB |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This is a multi-centre, single visit clinical investigation involving patients with known PCD
vs. age matched healthy volunteers. This study involves 1 visit which will last one (1) to
two (2) hours. Participants (and parent as applicable) will be asked for their consent to
participate in the study. A brief medical history will be recorded, including information
such as age, gender, height, weight, race, current medications and living environment. If the
participant is a PCD patient, they will also be asked about their disease history. Prior to
performing the nasal measurements, participants will receive instructions from study
personnel and have the opportunity to practice. All participants will have a brief nasal exam
and will also have to blow their nose before starting the measurements. Participants will be
asked to perform nasal nitric oxide measurements using the tidal breathing method followed by
the velum closed with expiration against resistance method.
The primary objective is to determine the feasibility and capability of the NIOX VERO to
discriminate participants with PCD from those that are healthy. Information collected in this
study will help researchers understand more about the diagnosis of and identification of
patients with PCD.
| Status | Completed |
| Enrollment | 163 |
| Est. completion date | April 28, 2017 |
| Est. primary completion date | October 2016 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 5 Years and older |
| Eligibility |
Inclusion Criteria: 1. Male and female patients 5 years and older. 2. Anatomically, is able to complete the nasal NO measurements in both nostrils. 3. Cohort 1 - PCD Patients: Patients must have a confirmed diagnosis of PCD from one of the PCD diagnostic centres based on clinical phenotype PLUS diagnosis made by at least 1 of the following (the specifics about how diagnosis was made must be documented in their medical file): - A nasal biopsy or scraping showing a hallmark PCD defect such as, an outer (+/- inner) dynein arm defect, microtubule defect, or - A genetic test positive for bi-alleilic mutations in a known PCD-causing gene associated with the diagnosis of PCD (e.g., ARMC4, C21orf59, CCDC39, CCDC40, CCDC65, CCDC164, CCDC103, CCDC114, CCDC151, CCNO, DNAAF1 (LRRC50), DNAAF2 (KTU), DNAAF3, DNAH5, DNAH11, DNAI1, DNAI2, DNAL1, DYX1C1, HEATR2, HYDIN, LRRC6, MCIDAS, NME8 (TXNDC3), ODA/IDA, OFD1, RPGR, RSPH3, RSPH4A, RSPH9, SPAG1, ZMYND10), or - EU Centres Only: A low nasal NO (determined by a chemiluminescent analyser) plus either: - at least 2 separate occasions with 'hallmark' changes on high-speed video microscopy, or - demonstration of mislocalisation of ciliary proteins by immunofluorescence microscopy. 4. Cohort 2 - Healthy Patients: Healthy, non-atopic, non-smoking patients (defined as patient with no airway or immune problems, no recent significant injury, no systemic infection, no systemic inflammation, no allergies or asthma). Exclusion Criteria: 1. Currently smokes or it has been less than 6 months from quitting. 2. Has had a nose bleed within the past 2 weeks. 3. Has acute respiratory symptoms or signs of an upper or lower respiratory tract infection. 4. Use of nasal medication as described below: - Xolair =180 days prior to nNO measurement - Oral or Systemic Corticosteroids =30 days prior to nNO measurement - Inhaled, nebulized, or intranasal corticosteroids =30 days prior to nNO measurement - Nasal or oral decongestants or antihistamines =14 days prior to nNO measurement - Leukotriene receptor antagonists =30 days prior to nNO measurement 5. Has an obstruction or anatomy that prevents a nasal measurement from being performed (as confirmed by simple visual inspection by the Investigator). 6. Has Cystic Fibrosis. 7. Has a documented primary or acquired immunodeficiency. 8. Is undergoing treatment with NO-releasing drugs (such as nitrates or molsidomine). 9. Has had food or beverage intake (other than water) or has participated in strenuous exercise within 1 hour of nasal NO measurement 10. Is unwilling or unable to provide consent to participate (self, parent or legal guardian). 11. PCD Patients Only: Has mutations with RSPH1 since nasal NO may not be low in these patients. 12. PCD Patients Only: Has not had a standard clinical evaluation to address other potential causes of chronic oto-sino- pulmonary disease. 13. Healthy Patients Only: Atopy or the presence of any of the following: a recent significant injury (i.e., within 1-2 weeks), systemic inflammation, airway or immune problem, asthma or allergies. 14. In the US only: Patients may not be related to a member of the Study Personnel. |
| Country | Name | City | State |
|---|---|---|---|
| Denmark | Denmark | Copenhagen | |
| France | Paris | Paris | |
| Germany | Germany | Munster | |
| United States | Chapel Hill | Chapel Hill | North Carolina |
| United States | St Louis | Saint Louis | Missouri |
| Lead Sponsor | Collaborator |
|---|---|
| Aerocrine AB |
United States, Denmark, France, Germany,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The primary endpoint will be the analysis of the means of the successful nNO measurements in Subjects with PCD as compared with Healthy Subjects in the Evaluable Population. | After a single 1-2 hour visit |